Ditropan® is indicated for the symptomatic treatment of urge urinary incontinence and/or increased urinary frequency as may occur in patients with unstable bladder.
Paediatric population. Oxybutynin is indicated for children over 5 years of age::
Ditropan® 5 mg sis presented in round, biconvex, light blue tablets with a central score line on one side with the inscription “OXB5” on the opposite side. The tablet can be divided into equal doses.
Each tablet contains 5 mg of oxybutynin hydrochloride.
Excipients with known effect: each tablet contains 152.2 mg of lactose.
The taste of the tablets is not pleasant, and they should be swallowed whole or divided with half a glass of water/liquid.
Adults
The dosage is 5 mg 3 times a day (3 tablets), although the 3 can also be administered together at the end of the day in case of nocturnal urination disorders. The daily amount can be increased up to a maximum of 5 mg four times a day to obtain a clinical response, as long as the side effects are well tolerated. After initial monitoring, a reduced maintenance dose can be introduced. The product must be swallowed together with a significant amount of liquid, to ensure transit through the esophagus.
Paediatric population
Niños mayores de 5 años: la posología es de 2 comprimidos al día, espaciados al menos 4 horas.
Niños menores de 5 años: No se recomienda el medicamento en este grupo de edad.
Older people
The dose must be adjusted individually, and the final dose will depend on the individual response and tolerance to adverse effects.
Ownership: CHEPLAPHARM Arzneimittel GmbH.
Comercialized by: Marketed and distributed in Spain by Laboratorios Rubió as a local representative.
